0001209191-20-048318.txt : 20200825 0001209191-20-048318.hdr.sgml : 20200825 20200825214516 ACCESSION NUMBER: 0001209191-20-048318 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200821 FILED AS OF DATE: 20200825 DATE AS OF CHANGE: 20200825 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Funtleyder Leslie D. CENTRAL INDEX KEY: 0001775394 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38898 FILM NUMBER: 201134021 MAIL ADDRESS: STREET 1: C/O APPLIED THERAPEUTICS, INC. STREET 2: 340 MADISON AVENUE, 19TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10173 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Applied Therapeutics Inc. CENTRAL INDEX KEY: 0001697532 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 545 5TH AVENUE, SUITE 1400 CITY: NEW YORK STATE: NY ZIP: 10017 BUSINESS PHONE: 212-220-9319 MAIL ADDRESS: STREET 1: 545 5TH AVENUE, SUITE 1400 CITY: NEW YORK STATE: NY ZIP: 10017 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-08-21 0 0001697532 Applied Therapeutics Inc. APLT 0001775394 Funtleyder Leslie D. C/O APPLIED THERAPEUTICS, INC. 545 FIFTH AVENUE, SUITE 1400 NEW YORK NY 10017 1 0 0 0 Common Stock 2020-08-21 4 M 0 20000 4.70 D 37148 D Common Stock 2020-08-24 4 S 0 13539 23.42 D 23609 D Common Stock 2020-08-24 4 S 0 6461 24.18 A 17148 D Stock Option (Right to Buy) 4.70 2020-08-21 4 M 0 20000 0.00 D 2029-03-06 Common Stock 20000 70502 D Compensatory options granted under Applied Therapeutics, Inc.'s 2016 Equity Incentive Plan, exercised pursuant to the reporting person's written trading plan, providing for the sale of shares underlying compensatory options in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Sales made pursuant to the reporting person's written trading plan, providing for the sale of shares underlying compensatory options in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Weighted average price. These shares were sold in multiple transactions at prices ranging from $22.9400 to $23.8600 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Weighted average price. These shares were sold in multiple transactions at prices ranging from $23.9700 to $24.4100 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. These options became fully vested on May 28, 2019. /s/ Shoshana Shendelman as attorney-in-fact 2020-08-25